High Content & Phenotypic Screening 2016
Date: Tuesday, 10 May 2016 – Wednesday, 11 May 2016
Location: Cambridge, UK
“Phenotypic screening was the primary mechanism of drug discovery for decades before the development of genomics enabled target selection, so this revival of interest in phenotypic screening is really a return to the past. …But of the 50 first-in-class new molecular entities (NMEs) approved for clinical use, 28 (56%) were discovered using a phenotypic approach, while 17 (34%) were target-based discoveries. … Phenotypic screening has received quite a bit of attention, and has become an increasingly popular approach, due to recent analyses showing that more NMEs have been discovered using phenotypic assays.
If you want to know more about this topic, I recommand to read this recent article : “Bridget K. Wagner (2015): The resurgence of phenotypic screening in drug discovery and development, Expert Opinion on Drug Discovery, DOI: 10.1517/17460441.2016.1122589“, where I took these sentences or going to the event on this topic :”High Contet & Phenotypic Screening 2016” in UK.
I hope to be there. We are preparing another one in Rennes in France with ELRIGfr association. Annoucement will followed in the next few weeks! Thus don’t forget to follow us!